ArticleExperimental and therapeutic medicine2019
LncRNA TUG1 promotes the development of osteosarcoma through RUNX2.
Article in Experimental and therapeutic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The value of lncRNAs as prognostic biomarkers on clinical outcomes in osteosarcoma: a meta-analysis.BMC cancer · 2021Pooled it
- LncRNA MCM3AP-AS1 is a potential prognostic marker for osteosarcoma and promotes its development by targeting miR-205-5p.Discover oncology · 2026Article
- Regorafenib-Induced Stress Response Alters the Bioenergetic Profile of Osteosarcoma Cells and Modulates Gene Expression Associated with Metabolic regulation-a Potential Mechanism of Osteosarcoma Treatment-Related Adaptation.Cancer management and research · 2026Article
- LncRNA TUG1 and its Molecular Mechanisms in Human Cancer.Current molecular medicine · 2025Review
- A comprehensive overview of liquid biopsy applications in pediatric solid tumors.NPJ precision oncology · 2024Review
- Review
- Long non-coding RNA NR2F2-AS1 regulates human osteosarcoma growth and metastasis through miR-425-5p-mediated HMGB2.International journal of clinical oncology · 2022Article
- Oncogenic Dysregulation of Circulating Noncoding RNAs: Novel Challenges and Opportunities in Sarcoma Diagnosis and Treatment.Cancers · 2022Review
- miR-204-5p is sponged by TUG1 to aggravate neuron damage induced by focal cerebral ischemia and reperfusion injury through upregulating COX2.Cell death discovery · 2022Article
- Selection of lncRNAs That Influence the Prognosis of Osteosarcoma Based on Copy Number Variation Data.Journal of oncology · 2022Article
- Serum-Based lncRNA ANRIL, TUG1, UCA1, and HIT Expressions in Breast Cancer Patients.Disease markers · 2022Article
- Preoperative Predictors of Early Mortality Risk in People with Osteosarcoma of the Extremities Treated with Standard Therapy.Cancer management and research · 2022Article
- Discovery of New Therapeutic Targets for Osteosarcoma Treatment Based on Immune-Related lncRNAs in the Tumor Microenvironment.BioMed research international · 2022Article
- The Emerging Role of Long Non-Coding RNAs in Esophageal Cancer: Functions in Tumorigenesis and Clinical Implications.Frontiers in pharmacology · 2022Review
- Circulating Long Non-Coding RNAs as Novel Potential Biomarkers for Osteogenic Sarcoma.Cancers · 2021Review
- LncRNA-TUG1 promotes the progression of infantile hemangioma by regulating miR-137/IGFBP5 axis.Human genomics · 2021Article
- Regulation of RUNX proteins by long non-coding RNAs and circular RNAs in different cancers.Non-coding RNA research · 2021Review
- Role of long noncoding RNA taurine-upregulated gene 1 in cancers.Molecular medicine (Cambridge, Mass.) · 2021Review
- The Involvement of Long Non-Coding RNAs in Bone.International journal of molecular sciences · 2021Review
- Total Glucosides of Paeony Inhibited Autophagy and Improved Acute Kidney Injury Induced by Ischemia-Reperfusion via the lncRNA TUG1/miR-29a/PTEN Axis.Drug design, development and therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lncRNA taurine-upregulated gene 1 (TUG1) is known to serve a role as an oncogene in the development of a number of human malignancies. However, the functionality of TUG1 in osteosarcoma remains poorly characterized. Therefore, the aim of the present study was to explore the role of TUG1 in osteosarcoma. TUG1 expression in tumor tissues, adjacent healthy tissues and plasma from 40 osteosarcoma patients and 40 healthy controls was detected using reverse transcription-quantitative PCR. Receiver operating characteristic curves were used to analyze the diagnostic value of TUG1 for osteosarcoma while the prognostic value of TUG1 for osteosarcoma was analyzed using the Kaplan-Meier method. TUG1 expression vectors and siRNAs were transfected into MG-63 and U2OS osteosarcoma cell lines, and the effects on osteosarcoma cell viability, migration and invasion were tested using Cell Counting kit-8 and Transwell assays. The effects of TUG1 overexpression on runt-related transcription factor 2 (RUNX2) expression were also detected using western blotting. TUG1 expression was found to be significantly higher in osteosarcoma tissues compared with adjacent healthy tissues, and in the plasma of osteosarcoma patients compared with healthy controls. TUG1 expression also exhibited significant diagnostic and prognostic value for osteosarcoma. TUG1 overexpression and knockdown respectively increased and reducedosteosarcoma cell viability, migration and invasion. In addition, TUG1 overexpression upregulated RUNX2 expression. These results suggest that lncRNA TUG1 may promote the development of osteosarcoma by modulating RUNX2 and TUG1 expression, which can serve as prognostic and diagnostic markers for this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.